Page 131 - 南京医科大学学报自然科学版

第44卷第3期 查 蔷，李建勇，沈文怡. 慢性粒单核细胞白血病合并自身免疫性疾病研究进展［J］.
2024年3月 南京医科大学学报（自然科学版），2024，44（3）：417-422 ·421 ·

acid ⁃ siglec axis in human immune regulation，involve⁃ （1）：65-73
ment in autoimmunity and cancer and potential therapeu⁃ ［25］ MEYER A，PARMAR P J，SHAHRARA S. Significance
tic treatments［J］. Int J Mol Sci，2021，22（11）：5774 of IL⁃7 and IL⁃7R in RA and autoimmunity［J］. Autoim⁃
［13］ AMBINDER A J，MILLER J，DEZERN A E. Autoimmune mun Rev，2022，21（7）：103120
disease in CMML⁃the chicken or the egg?［J］. Best Pract ［26］ FRANZINI A，POMICTER A D，YAN D Q，et al. The tran⁃
Res Clin Haematol，2020，33（2）：101136 scriptome of CMML monocytes is highly inflammatory
［14］ ZHAO L P，FENAUX P. What role for somatic mutations and reflects leukemia⁃specific and age⁃related alterations
in systemic inflammatory and autoimmune diseases asso⁃ ［J］. Blood Adv，2019，3（20）：2949-2961
ciated with myelodysplastic neoplasms and chronic myelo⁃ ［27］ NIYONGERE S，LUCAS N，ZHOU J M，et al. Heteroge⁃
monocytic leukemias?［J］. Leukemia，2023，37（9）：1943 neous expression of cytokines accounts for clinical diversity
［15］ ZHAO L P，BOY M，AZOULAY C，et al. Genomic land⁃ and refines prognostication in CMML［J］. Leukemia，
scape of MDS/CMML associated with systemic inflamma⁃ 2019，33（1）：205-216
tory and autoimmune disease［J］. Leukemia，2021，35 ［28］ ANDINA N，DE MEURON L，SCHNEGG⁃KAUFMANN
（9）：2720-2724 A S，et al. Increased inflammasome activation is associat⁃
［16］ YEATON A，CAYANAN G，LOGHAVI S，et al. The im⁃ ed with aging and chronic myelomonocytic leukemia dis⁃
pact of inflammation⁃induced tumor plasticity during mye⁃ ease severity［J］. J Immunol，2023，210（5）：580-589
loid transformation［J］. Cancer Discov，2022，12（10）： ［29］ JACHIET V，HADJADJ J，ZHAO L P，et al. Dysimmune
2392-2413 manifestations associated with myelodysplastic neoplasms
［17］ AGRAWAL M，NIROULA A，CUNIN P，et al. TET2⁃mu⁃ and chronic myelomonocytic leukaemias［J］. Bull Cancer，
tant clonal hematopoiesis and risk of gout［J］. Blood， 2023，110（11）：1147-1155
2022，140（10）：1094-1103 ［30］MONTORO J ，GALLVR L，MERCHAN B，et al. Autoim⁃
［18］ MILLER P G，QIAO D，ROJAS⁃QUINTERO J，et al. Asso⁃ mune discorders are common in myelodysplastic syn⁃
ciation of clonal hematopoiesis with chronic obstructive drome patients and conter an adverse impact on outcomes
pulmonary disease［J］. Blood，2023，141（6）：682 ［J］. Ann Hematol，2018，97（8）：1349-1356
［19］ ZHAO L P，SCHELL B，SÉBERT M，et al. Prevalence of ［31］ MEKINIAN A，GRIGNANO E，BRAUN T，et al. Systemic
UBA1 mutations in MDS/CMML patients with systemic in⁃ inflammatory and autoimmune manifestations associated
flammatory and auto ⁃ immune disease［J］. Leukemia， with myelodysplastic syndromes and chronic myelomono⁃

2021，35（9）：2731-2733 cytic leukaemia：a French multicentre retrospective study
［20］ CAMACHO⁃BYDUME C，WANG T，SEES J A，et al. Spe⁃ ［J］. Rheumatology，2016，55（2）：291-300
cific class I HLA supertypes but not HLA zygosity or ex⁃ ［32］ FERNANDEZ ⁃ SANTAMARIA R，SATITSUKSANOA P.
pression are associated with outcomes following HLA ⁃ Engineered IL⁃10：a matter of affinity［J］. Allergy，2022，
matched allogeneic hematopoietic cell transplant：HLA 77（3）：1067-1069
supertypes impact allogeneic HCT outcomes［J］. Trans⁃ ［33］ KIPFER B，DAIKELER T，KUCHEN S，et al. Increased
plant Cell Ther，2021，27（2）：142-142 cardiovascular comorbidities in patients with myelodys⁃
［21］ MASETTI R，TIRI A，TIGNANELLI A，et al. Autoimmuni⁃ plastic syndromes and chronic myelomonocytic leukemia
ty and cancer［J］. Autoimmun Rev，2021，20（9）：102882 presenting with systemic inflammatory and autoimmune
［22］ ILCHOVSKA D D，BARROW D M. An overview of the NF manifestations［J］. Semin Hematol，2018，55（4）：242-
⁃κB mechanism of pathophysiology in rheumatoid arthri⁃ 247
tis，investigation of the NF⁃κB ligand RANKL and related ［34］ ROUPIE A L，GUEDON A，TERRIER B，et al. Vasculitis
nutritional interventions［J］. Autoimmun Rev，2021，20 associated with myelodysplastic syndrome and chronic
（2）：102741 myelomonocytic leukemia：French multicenter case⁃con⁃
［23］MUTO T，WALKER C S，CHOI K，et al. Adaptive res ⁃ trol study［J］. Semin Arthritis Rheum，2020，50（5）：879-
ponse to inflammation contributes to sustained myelopoie⁃ 884
sis and confers a competitive advantage in myelodysplastic ［35］ MERLEVEDE J，DROIN N，QIN T T，et al. Mutation
syndrome HSCs［J］. Nat Immunol，2020，21（5）：535-545 alleleburdenremainsunchangedinchronicmyelomonocytic
［24］ PATNAIK M M，VALLAPUREDDY R，YALNIZ F F，et leukaemia responding to hypomethylating agents［J］. Nat
al. Therapy related ⁃ chronic myelomonocytic leukemia Commun，2016，7：10767
（CMML）：molecular，cytogenetic，and clinical distinc⁃ ［36］ SYMEONIDIS A，VAN BIEZEN A，DE WREEDE L，et
tions from de novo CMML［J］. Am J Hematol，2018，93 al. Achievement of complete remission predicts outcome